Dallas, Texas–(Newsfile Corp. – August 20, 2020) – Puration, Inc. (OTC Pink: PURA) today announced reporting $1.6 million in sales year to date. The company has published its Q2 2020 report with OTC Markets. Management highlights the company’s ongoing sales strength driven by COVID-19 resilient demand for its EVERx CBD Sports Water.
PURA Logo
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6696/62197_ade52f8b04d4a850_001full.jpg
PURA has scheduled an earnings update to be published next week on Tuesday, August 25, 2020 to highlight the company’s performance in more detail. The update will include a review of the company’s ongoing base revenue from the sales of its EVERx CBD Sports Water in addition to updates on the company’s progress in the issuance of a dividend distribution to PURA shareholders resulting from the recent declaration of a stock dividend in conjunction with the sale of PURA’s cannabis cultivation operation to PAO Group, Inc. (OTC Pink: PAOG). The update next week will also include the latest on the company’s ongoing acquisition campaign.
For more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
[email protected]
(800) 861-1350
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/62197